Vlad Taru
Overview
Explore the profile of Vlad Taru including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hofer B, Simbrunner B, Konigshofer P, Brusilovskaya K, Petrenko O, Taru V, et al.
United European Gastroenterol J
. 2024 Dec;
PMID: 39708052
Background: Portal hypertension (PH) resulting from static and dynamic intrahepatic changes drives liver-related complications even after removing the underlying aetiological factor. Objective: We investigated the impact of inflammation on the...
2.
3.
Hofer B, Simbrunner B, Konigshofer P, Brusilovskaya K, Petrenko O, Taru V, et al.
Dig Liver Dis
. 2024 Sep;
57(2):450-458.
PMID: 39343656
Background: Cirrhosis is associated with a proinflammatory environment. Aims: To analyse aetiology-specific inflammation patterns in compensated cirrhosis in animal models and patients. Methods: Portal pressure (PP), fibrosis (collagen proportionate area...
4.
Taru V, Szabo G, Mehal W, Reiberger T
J Hepatol
. 2024 Jun;
81(5):895-910.
PMID: 38908436
Chronic liver disease leads to hepatocellular injury that triggers a pro-inflammatory state in several parenchymal and non-parenchymal hepatic cell types, ultimately resulting in liver fibrosis, cirrhosis, portal hypertension and liver...
5.
Paternostro R, Kwanten W, Hofer B, Semmler G, Bagdadi A, Luzko I, et al.
J Hepatol
. 2024 Jun;
81(5):827-836.
PMID: 38823501
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of advanced chronic liver disease (ACLD). Portal hypertension drives hepatic decompensation and is best diagnosed by hepatic...
6.
Taru M, Tefas C, Neamti L, Minciuna I, Taru V, Maniu A, et al.
PLoS One
. 2024 May;
19(5):e0303971.
PMID: 38781158
Background: MASLD is a prevalent chronic liver condition with substantial clinical implications. This study aimed to assess the effectiveness of three new, elastography-based, scoring systems for advanced fibrosis ≥F3 (Agile...
7.
Taru M, Neamti L, Taru V, Procopciuc L, Procopet B, Lupsor-Platon M
Diagnostics (Basel)
. 2023 Feb;
13(4).
PMID: 36832276
Non-alcoholic fatty liver disease (NAFLD), and its progressive form, non-alcoholic steatohepatitis (NASH), represent, nowadays, real challenges for the healthcare system. Liver fibrosis is the most important prognostic factor for NAFLD,...
8.
Taru V, Indre M, Ignat M, Forgione A, Racs T, Olar B, et al.
J Gastrointestin Liver Dis
. 2021 Jun;
30(2):240-246.
PMID: 34174063
Background And Aims: Health-related quality of life is an essential part of managing chronically ill patients, including patients with chronic liver disease. Various methods are used to try to assess...